BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schneider G, Wirth M, Keller U, Saur D. Rationale for MYC imaging and targeting in pancreatic cancer. EJNMMI Res 2021;11:104. [PMID: 34637026 DOI: 10.1186/s13550-021-00843-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Demel UM, Wirth M, Yousefian S, Zhang L, Isaakidis K, Dönig J, Böger M, Singh N, Köse H, Haas S, Müller S, Schick M, Keller U. Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy. Haematologica 2023;108:555-67. [PMID: 36134453 DOI: 10.3324/haematol.2022.280995] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Pershina AG, Nevskaya KV, Morozov KR, Litviakov NV. Methods for assessing the effect of microRNA on stemness genes. Bûll sib med 2023;21:170-182. [DOI: 10.20538/1682-0363-2022-4-170-182] [Reference Citation Analysis]
3 Li Y, Elakad O, Yao S, von Hammerstein-Equord A, Hinterthaner M, Danner BC, Ferrai C, Ströbel P, Küffer S, Bohnenberger H. Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma. Metabolites 2022;12:652. [PMID: 35888776 DOI: 10.3390/metabo12070652] [Reference Citation Analysis]
4 Wirth M. Targeting the translational machinery to overcome apoptosis resistance in pancreatic cancer. Transl Oncol 2022;17:101343. [PMID: 35078019 DOI: 10.1016/j.tranon.2022.101343] [Cited by in F6Publishing: 1] [Reference Citation Analysis]